About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Plans and PBMs Would Be the Chief Beneficiaries
Medicare is proposing significant revisions to its Part D drug program. The biggest change: the elimination of antidepressants and immunosuppressants as “protected classes” on formularies in 2015 and the removal of antipsychotics in 2016.
Retrospective Analysis of Azithromycin Versus Fluoroquinolones for the Treatment of Legionella Pneumonia
A single-center retrospective study that compared clinical outcomes of patients with Legionella pneumonia treated with azithromycin versus fluoroquinolones for more than 12 years found that azithromycin appears to have clinical efficacy similar to fluoroquinolones.
Jerod L. Nagel, PharmD; Rachel E. Rarus, PharmD; Alex W. Crowley, PharmD; and Cesar Alaniz, PharmD
Overexpression of human epidermal growth factor receptor 2 (HER2) is an important factor in cancer survival, proliferation, and metastasis. Agents that target HER2-positive tumors are used with traditional chemotherapies, with other targeted therapies, or as monotherapy to treat metastatic breast cancers.
The American Cancer Society estimates that 40,000 women will die from breast cancer this year. But thanks to steady progress in the war on cancer, millions of U.S. women with a history of the disease are alive today. Key statistics on survival rates, therapies in use, and treatment costs are provided.
Height and weight errors confound electronic prescribing.
Matthew Grissinger, RPh, FASCP
FDA Proposal Seeks to Improve Early Warning System
Dapaglifozin (Farxiga) for improved glycemic control in type-2 diabetes, and trametinib (Mekinist) in combination with dabrafenib (Tafinlar) for the treatment of advanced, unresectable melanoma
Marvin M. Goldenberg, PhD, RPh, MS
Laura Dineen, Connie Law, Rebecca Scher, and Eunice Pyon, BS, PharmD